soluble CD40L
Selected indexed studies
- The Role of Soluble CD40L Ligand in Human Carcinogenesis. (Anticancer Res, 2018) [PMID:29715163]
- Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. (Pharmacol Ther, 2021) [PMID:33091428]
- Interleukin-31 and soluble CD40L: new candidate serum biomarkers that predict therapeutic response in multiple sclerosis. (Neurol Sci, 2022) [PMID:35849199]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- The Role of Soluble CD40L Ligand in Human Carcinogenesis. (2018) pubmed
- Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. (2021) pubmed
- Interleukin-31 and soluble CD40L: new candidate serum biomarkers that predict therapeutic response in multiple sclerosis. (2022) pubmed
- Soluble CD40L and its role in essential hypertension: diagnostic and therapeutic implications. (2008) pubmed
- Soluble CD40L activates soluble and cell-surface integrin αvβ3, α5β1, and α4β1 by binding to the allosteric ligand-binding site (site 2). (2021) pubmed
- Metabolic syndrome, soluble CD40L, and biomarkers of endothelial dysfunction in people living with HIV. (2023) pubmed
- CD40 Ligand Deficiency. (2020) pubmed
- High-flux hemodialysis with polymethylmethacrylate membranes reduces soluble CD40L, a mediator of cardiovascular disease in uremia. (2025) pubmed
- Soluble CD40L and cardiovascular risk in women. (2001) pubmed
- Soluble FAS Ligand Enhances Suboptimal CD40L/IL-21-Mediated Human Memory B Cell Differentiation into Antibody-Secreting Cells. (2021) pubmed